Sagimet Biosciences (NASDAQ:SGMT) is a biopharmaceutical company dedicated to developing a range of novel therapeutics aimed at addressing critical needs in metabolic diseases, with a significant focus on nonalcoholic steatohepatitis (NASH) and other liver-related disorders. Their innovative approach leverages unique insights into metabolism and disease mechanisms to design targeted, effective treatments. Currently, Sagimet Biosciences is advancing its lead candidate through clinical trials, demonstrating a commitment to improving patient outcomes in areas with significant unmet medical needs. The company's objectives are deeply rooted in advancing healthcare through groundbreaking research, aiming to deliver transformative therapies to patients worldwide.